NetScientific Plc’s (LON:NSCI) management team and portfolio focus have been totally revitalised by Francois Martelet, who took up the position of chief executive last June.
That’s the view of the company’s chairman Sir Richard Sykes ahead of the company’s Capital Markets Day at the London Stock Exchange, which happens today.
“We now have a focused portfolio of assets which are close to commercialisation and which offer the scope for significant value creation,” Sykes said in a statement.
“We look forward to highlighting the key jewels in our crown, and to explaining how they offer opportunities both to provide patient benefit and shareholder value."
Sykes and Martelet will outline to attending investors the next steps for NetScientific in maximising value from its portfolio companies. The LSE organised event will also feature representatives from the businesses that NetScientific is invested in.
In a separate statement, NetScientific announced the appointment of Dr Massimo Cristofanilli by portfolio company Vortex Biosciences to be chairman of its newly formed scientific advisory board.
"Vortex Biosciences is at a pivotal point as its circulating tumour cell enrichment system, the VTX-1, moves towards commercialisation,” Martelet said.
“The appointment of Dr. Cristofanilli, who will be joining to spearhead the creation of Vortex's world class Scientific Advisory Board, will help underpin their clinical strategy as the company moves through this transformational period."